국내 의약품 특성을 반영한 ATC 분류 적용 및 활용방안 연구
- Type
- Research report
- Issued Date
- 2022-12
- Publisher
- 건강보험심사평가원
- Table Of Contents
- 제1장 연구의 개요 ···························································· 1
1. 연구 배경···························································································· 1
가. WHO ATC/DDD에 대한 이해································································· 1
나. 국외 의약품 ATC 코드 부여 현황 및 활용············································ 5
다. 국내 의약품 ATC 코드 부여 현황 및 활용·········································· 17
라. 국내 정치·제도적 현황·········································································· 25
2. 연구 목적 및 필요성········································································· 27
가. WHO-ATC 기준 적용이 어려운 국내 의약품 특성을 반영한
ATC 분류 적용 방안 및 기준 개발······················································· 27
나. 국·내외 다양한 분야에서의 ATC 코드 사용 현황을 파악하여 국가공인 ATC 분류로서의 활용가치 향상 방안 마련··························· 27
다. 기존 ATC 코드 부여 절차의 효율성 향상을 위한 방안 마련··············· 28
제2장 연구내용 및 방법 ···························································· 29
1. 연구 개발의 추진전략·방법······························································· 29
2. 총괄 연구 개발의 추진체계······························································· 30
3. 미분류 원인 및 유형 분류································································· 31
가. 현 ATC 부여 코드 목록 중 5단계 미분류 품목에 대한 유형 분류······ 31
나. ATC 5단계 코드 미분류 품목의 원인 파악·········································· 58
4. 국내·외 ATC 분류체계 조사····························································· 59
5. ATC 코드 분류 대상 선정 및 분류 기준(안) 개발·························· 61
가. ATC 5단계 미분류 유형에 대한 분류 정의 및 ATC 코드 분류 기준 마련 ·························· 61
나. 국내 K-ATC 분류 기준 검증······························································ 63
6. 의약품 ATC 코드 관리·활용·발전 방안············································· 64
가. ATC 분류 관련 문제점 파악································································ 64
나. 국외 ATC DB 운영 사례 검토····························································· 64
다. 관련 선행 연구 등 체계적 문헌고찰을 통한 사례 수집························ 65
라. DB운영 활용성 증대를 위한 관리 방안 제언········································ 65
마. WHO-ATC와 국내 K-ATC의 관리 운영 방안 제언··························· 65
제3장 연구 결과 ···························································· 67
1. 국내 허가 의약품 ATC 코드 부여 현황 분석··································· 67
가. 국내 허가 의약품 현황········································································· 67
나. 의약품 품목구분별 ATC 코드 부여 현황 분석····································· 69
2. 국내 WHO-ATC 5단계 미분류 원인 분석······································· 77
가. WHO-ATC 분류상 하위단계가 부재한 코드······································· 77
나. 미분류 의약품의 관련 카테고리···························································· 81
다. WHO-ATC 5단계 코드 미분류 의약품 분석 제외 조건······················ 82
라. 대분류별 미분류 원인 현황 분석·························································· 83
3. 국내 기관 WHO-ATC 활용 및 제한점············································ 97
가. 설문조사 기관······················································································· 97
나. 문항의 구성·························································································· 97
다. 조사결과································································································ 98
4. 국내·외 ATC 분류체계 조사··························································· 101
가. 의료기관, 정부 및 유관기관 등 국내·외 ATC 코드 사용 현황 조사·· 101
나. 국내·외 분류체계 개발 기관 및 관련 선행 연구 조사························ 102
다. WHO-UMC WHODrug 시스템 조사·················································· 104
라. 국제 기준과 통합된 ATC 코드 활용사례 – WHODrug 정보사전······· 104
마. 국가별 ATC 분류체계 파악································································ 125
5. 국내 의약품 특성을 반영한 한국형 ATC(K-ATC) 코드 분류······ 161
가. 한국형 ATC 코드 신설 원칙(안) ······················································· 161
나. 5단계 미분류 원인 및 분류기준(안) ··················································· 175
다. K-ATC 분류 신설 예시····································································· 178
라. K-ATC 활용성 증대를 위한 시스템 구축········································· 199
마. K-ATC 시스템의 기대효과································································ 201
바. K-ATC 활용 발전을 위한 운영체계 제언········································· 202
사. K-ATC 의약품 분류 시스템 발전을 위한 제언································· 206
6. 국내 의약품 특성을 반영한 K-ATC 시스템 구축을 위한 연구 경과 207
제4장 연구 결과에 대한 기여도, 기대효과 및 활용방안 ···························································· 209
1. 기여도····························································································· 209
2. 기대효과·························································································· 210
3. 활용방안·························································································· 211
4. 제언································································································· 213
◾참고 문헌··················································································· 214
◾부록 목차··················································································· 219
- Publisher
- 건강보험심사평가원
- Location
- KOR
- Citation
- 김은영. (2022-12). 국내 의약품 특성을 반영한 ATC 분류 적용 및 활용방안 연구.
- 파일 목록
-
-
Download
국내 의약품 특성을 반영한 ATC 분류 적용 및 활용방안 연구.pdf
기타 데이터 / 65.64 MB / Adobe PDF
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.